Real-World Effectiveness and Safety of Adding Trimetazidine to Standard Antianginal Therapy in Patients with Stable Angina: Egyptian Cohort Findings of the COMBINE Angina Study.
7 affiliations
- 1Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt.
- 2Faculty of Medicine, Menoufia University, Shebin El-Kom 32511, Egypt.
- 3Faculty of Medicine, Sohag University, Sohag 82524, Egypt.
- 4Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
- 5Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh 33516, Egypt.
- 6Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
- 7Faculty of Medicine, Beni Suef University, Beni Suef 62511, Egypt.
Abstract
Background/Objectives: Stable angina is a significant health issue in Egypt, often showing poor responses to standard treatments. This study examines the effectiveness and safety of early combination therapy with trimetazidine and either a β-blocker or a calcium channel blocker (CCB) among Egyptian patients with stable angina. Methods: This sub-analysis of the Egyptian cohort from the COMBINE Angina study included patients with stable angina (CCS class II-III) who remained symptomatic after 2-4 weeks of β-blocker or CCB monotherapy. Patients received trimetazidine 35 mg modified-release twice daily as an add-on treatment for 4 months. The primary outcome was the Seattle Angina Questionnaire (SAQ-7) summary score, with secondary outcomes including SAQ-7 domain scores, CCS class, frequency of angina attacks, nitrate use, treatment satisfaction, adherence, and safety. Results: In the global COMBINE study involving 578 patients, the Egyptian cohort had 138 participants with an average age of 58.3 years. The SAQ-7 summary score improved from 42.2 at baseline to 76.8 at month 4 (mean change 34.6 points, 95% CI 31.3 to 38.0; p < 0.0001). All 138 patients contributed data at every visit for the SAQ-7 summary score. Patients in CCS class I increased from 0% to 56.5%, weekly angina attacks fell from 5.0 to 1.7 (p < 0.0001), and short-acting nitrate use decreased from 2.9 to 1.0 doses per week (p < 0.0001). Patient satisfaction was about 75%, and physician satisfaction reached 83% by month 4. Medication adherence also improved (MARS-5 score: 20.8 to 22.7), and two non-serious, treatment-related adverse events (nausea and somnolence) were reported in a single patient (0.7%), with no serious or fatal events. Conclusions: In Egyptian patients with stable angina, implementing an early combination strategy incorporating trimetazidine with first-line β-blocker or CCB therapy was associated with clinically meaningful improvements in angina symptoms, functional status, and quality of life, with good tolerability and high satisfaction. As the study was observational and single-arm, these findings are provisional and require confirmation in further long-term controlled studies.
Related
- Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
- Cost-effectiveness of prehospital high-sensitivity troponin i testing versus standard emergency department care in patients with suspected acute coronary syndrome in France
- Phase 1 Study of Safety and PK With A Combination of Omeprazole and Trimetazidine for Fatty Acid Oxidation Inhibition in Patients With Advanced Solid Tumors.
- Cost-effectiveness analysis of FundoRing versus standard one-anastomosis gastric bypass: up to 3-year results of a randomized controlled trial
- Assessment of functional profile and fatigue in Egyptian patients with active secondary progressive MS
BibTeX
@article{sobhy2026realworld,
title = {{Real-World Effectiveness and Safety of Adding Trimetazidine to Standard Antianginal Therapy in Patients with Stable Angina: Egyptian Cohort Findings of the COMBINE Angina Study.}},
author = {Mohamed Sobhy and Mohamed Fahmy Elnoamany and Mohamed Loutfi and Sharaf Eldeen Mahmoud and Mohamed Abdel Ghany and Mohamed Kamal Salama and Adham Ahmed Abdeltawab and Yasser A Abdelhady},
journal = {Medical sciences (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/medsci14060620},
url = {https://europepmc.org/article/MED/42930538},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real-World Effectiveness and Safety of Adding Trimetazidine to Standard Antianginal Therapy in Patients with Stable Angina: Egyptian Cohort Findings of the COMBINE Angina Study.
AU - Mohamed Sobhy
AU - Mohamed Fahmy Elnoamany
AU - Mohamed Loutfi
AU - Sharaf Eldeen Mahmoud
AU - Mohamed Abdel Ghany
AU - Mohamed Kamal Salama
AU - Adham Ahmed Abdeltawab
AU - Yasser A Abdelhady
PY - 2026
DA - 2026/09/30
JO - Medical sciences (Basel, Switzerland)
DO - 10.3390/medsci14060620
UR - https://europepmc.org/article/MED/42930538
AB - Background/Objectives: Stable angina is a significant health issue in Egypt, often showing poor responses to standard treatments. This study examines the effectiveness and safety of early combination therapy with trimetazidine and either a β-blocker or a calcium channel blocker (CCB) among Egyptian patients with stable angina. Methods: This sub-analysis of the Egyptian cohort from the COMBINE Angina study included patients with stable angina (CCS class II-III) who remained symptomatic after 2-4 weeks of β-blocker or CCB monotherapy. Patients received trimetazidine 35 mg modified-release twice daily as an add-on treatment for 4 months. The primary outcome was the Seattle Angina Questionnaire (SAQ-7) summary score, with secondary outcomes including SAQ-7 domain scores, CCS class, frequency of angina attacks, nitrate use, treatment satisfaction, adherence, and safety. Results: In the global COMBINE study involving 578 patients, the Egyptian cohort had 138 participants with an average age of 58.3 years. The SAQ-7 summary score improved from 42.2 at baseline to 76.8 at month 4 (mean change 34.6 points, 95% CI 31.3 to 38.0; p < 0.0001). All 138 patients contributed data at every visit for the SAQ-7 summary score. Patients in CCS class I increased from 0% to 56.5%, weekly angina attacks fell from 5.0 to 1.7 (p < 0.0001), and short-acting nitrate use decreased from 2.9 to 1.0 doses per week (p < 0.0001). Patient satisfaction was about 75%, and physician satisfaction reached 83% by month 4. Medication adherence also improved (MARS-5 score: 20.8 to 22.7), and two non-serious, treatment-related adverse events (nausea and somnolence) were reported in a single patient (0.7%), with no serious or fatal events. Conclusions: In Egyptian patients with stable angina, implementing an early combination strategy incorporating trimetazidine with first-line β-blocker or CCB therapy was associated with clinically meaningful improvements in angina symptoms, functional status, and quality of life, with good tolerability and high satisfaction. As the study was observational and single-arm, these findings are provisional and require confirmation in further long-term controlled studies.
SN - 2076-3271
ER -